Eli Lilly and Company (NYSE:LLY) Stock Price Down 3.8% - Time to Sell?

Key Points

• Eli Lilly's stock price fell by 3.8% during trading, closing at $713.87, with a significant trading volume increase of 25% compared to its average.
• Analysts' ratings are mixed, with one strong buy, fourteen buy, and nine hold ratings; the average price target is $939.61.
• The company's latest earnings report exceeded expectations, with earnings of $6.31 per share and revenue of $15.56 billion, a 37.6% increase compared to the previous year.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s stock price was down 3.8% during trading on Thursday . The stock traded as low as $712.05 and last traded at $713.87. Approximately 5,106,494 shares changed hands during trading, an increase of 25% from the average daily volume of 4,086,542 shares. The stock had previously closed at $741.85.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on LLY shares. DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. Daiwa America downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Daiwa Capital Markets downgraded shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price objective for the company. in a research report on Sunday, August 17th. Berenberg Bank reissued a "hold" rating and set a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Finally, UBS Group reduced their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $939.61.

Eli Lilly and Company Stock Down 3.8%

The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a market capitalization of $675.65 billion, a PE ratio of 46.66, a PEG ratio of 1.04 and a beta of 0.47. The company's 50 day simple moving average is $736.05 and its 200-day simple moving average is $768.68.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the prior year, the company posted $3.92 EPS. The business's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In related news, Director Jamere Jackson purchased 200 shares of the firm's stock in a transaction dated Friday, August 8th. The shares were purchased at an average price of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director directly owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 4,514 shares of company stock worth $2,894,841. Company insiders own 0.13% of the company's stock.

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently made changes to their positions in the business. Caldwell Trust Co bought a new stake in Eli Lilly and Company in the 2nd quarter worth $17,214,000. Silicon Valley Capital Partners grew its holdings in Eli Lilly and Company by 12.3% in the 2nd quarter. Silicon Valley Capital Partners now owns 18,121 shares of the company's stock worth $14,126,000 after acquiring an additional 1,990 shares during the last quarter. WT Wealth Management grew its holdings in Eli Lilly and Company by 1.8% in the 2nd quarter. WT Wealth Management now owns 814 shares of the company's stock worth $635,000 after acquiring an additional 14 shares during the last quarter. NWF Advisory Services Inc. grew its holdings in Eli Lilly and Company by 103.1% in the 2nd quarter. NWF Advisory Services Inc. now owns 1,974 shares of the company's stock worth $1,539,000 after acquiring an additional 1,002 shares during the last quarter. Finally, SevenBridge Financial Group LLC grew its holdings in Eli Lilly and Company by 18.4% in the 2nd quarter. SevenBridge Financial Group LLC now owns 7,192 shares of the company's stock worth $5,606,000 after acquiring an additional 1,116 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.